PERCEPTIVE ADVISORS LLC
Q4 2022 13F-HR Holdings
Net value change ($000)
+115,520
(3.4%)
New positions
13
Sold out positions
32
Turnover %
22.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MDGL | 190,930 | 887.5% |
| Horizon Therapeutics Public Ltd Co | 109,248 | NEW |
| VRNA | 75,950 | 147.2% |
| AMLX | 70,926 | 46.0% |
| SRPT | 56,163 | 200.8% |
| PCVX | 56,102 | NEW |
| FOLD | 51,747 | 18.1% |
| Prometheus Biosciences, Inc. | 46,739 | 53.9% |
| ZYME | 35,459 | NEW |
| NUVL | 34,981 | 108.7% |
Top Reduces (Value $000, Stocks/ETFs)
| Global Blood Therapeutics, Inc. | -158,145 | -100.0% |
| Mirati Therapeutics, Inc. | -95,197 | -48.9% |
| RLMD | -88,236 | -100.0% |
| CinCor Pharma, Inc. | -76,861 | -70.8% |
| Seagen Inc. | -43,313 | -100.0% |
| BELLUS Health Inc. | -35,125 | -32.5% |
| IOVA | -34,461 | -35.1% |
| SpringWorks Therapeutics, Inc. | -30,929 | -31.2% |
| CRNX | -30,586 | -29.3% |
| EW | -27,268 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
91,506
(2.6% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|